Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in conjunction with sale of shares in Oatly
Mandate

Vinge advises in conjunction with sale of shares in Oatly

December 08, 2016

Vinge has advised on the sale of the shares in Oatly.

Oatly was formed in the 1990s as a spin-off from a research facility at Lund University. Today, Oatly has established itself as one of the Nordic region’s leading trademarks within ethical and sustainable lifestyle. Oatly is currently active on 20 markets in Europe and Asia, and its turnover last year was approximately SEK 369 million.

Vinge’s team consisted of responsible partner Johan Larsson together with, among others, associates Joacim Rydergård and Johanna Wiberg (M&A), Malin Malm Waerme (intellectual property), senior counsel Qun Gu (China practice) and Pernilla Warg (project assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024